(Q36470056)

English

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma (English)

1 reference

Europe PubMed Central

14 August 2017

0 references

1 reference

based on heuristic

inferred from title

peritoneal carcinomatosis

1 reference

based on heuristic

inferred from title

3

object named as

Carl June

1 reference

Europe PubMed Central

14 August 2017

Ralph S Freedman

7

object named as

Ralph S Freedman

1 reference

Europe PubMed Central

14 August 2017

author name string

Renato Lenzi

1

1 reference

Europe PubMed Central

14 August 2017

Robert Edwards

2

1 reference

Europe PubMed Central

14 August 2017

Michael V Seiden

4

1 reference

Europe PubMed Central

14 August 2017

Michael E Garcia

5

1 reference

Europe PubMed Central

14 August 2017

Michael Rosenblum

6

1 reference

Europe PubMed Central

14 August 2017

publication date

12 December 2007

1 reference

Europe PubMed Central

14 August 2017

Journal of Translational Medicine

1 reference

Europe PubMed Central

14 August 2017

5

1 reference

Europe PubMed Central

14 August 2017

66

1 reference

Europe PubMed Central

14 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

1 December 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

https://scigraph.springernature.com/pub.10.1186/1479-5876-5-66

0 references

rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248163

30 September 2017

Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248163

30 September 2017

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248163

30 September 2017

Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248163

30 September 2017

Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248163

30 September 2017

Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248163

30 September 2017

Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248163

30 September 2017

Inhibition of angiogenesis in vivo by interleukin 12.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248163

28 June 2018

Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248163

21 September 2018

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/18076766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18076766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10

1 reference

https://pubmed.ncbi.nlm.nih.gov/18076766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18076766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1479-5876-5-66

1 reference

Europe PubMed Central

14 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36470056&oldid=1881835747"